Maraviroc: a CCR5 antagonist

Authors: Tan, LKK; Nelson, M

Source: Future HIV Therapy, Volume 2, Number 2, March 2008 , pp. 111-123(13)

Purchase options

The full text electronic article is available for purchase. You will be able to download the full text electronic article after payment.

$73.00 plus tax Refund Policy

More about this publication?

Future HIV Therapy keeps clinicians and researchers up to date with the significant advances that will enable us to develop new treatments to target the virus and any resistant strains that might develop, and also to improve side effects, adherence and education in therapy, and simplify drug regimens and reduce costs.
Editorial Board
Information for Authors
Submit a Paper
Subscribe to this Title
Information for Advertisers
Terms & Conditions
Information for Librarians
E-Access Trials

More like this?

In this: publication
By this: publisher
By this author: Tan, LKK ; Nelson, M

Content Key:

- Free

- New

- Open Access

- Subscribed

- Free Trial

Abstract:

HIV requires binding to both the CD4 molecule and a coreceptor to enable entry into the cell. CCR5 is a chemokine receptor that is utilized as a coreceptor by the majority of virus in early asymptomatic HIV infection. Maraviroc is a novel small molecule CCR5 antagonist which, in Phase IIb/III clinical trials up to 48weeks, has been shown to be efficacious as part of an optimized antiretroviral regimen against CCR5 tropic HIV-1 in treatment-experienced patients. A further trial has demonstrated its noninferiority to efavirenz in achieving a HIV viral load less than 400 copies/ml as part of highly active antiretroviral therapy in treatment-naive individuals. It has recently received regulatory approval for use in North America and Europe in treatment-experienced patients. With increasing use, the role of maraviroc in the treatment of HIV-infected patients will be more clearly defined.

Keywords: CCR5 antagonist; HIV-1; maraviroc; viral tropism

Document Type: Drug Evaluation

DOI: 10.2217/17469600.2.2.111